Search Results - "Swords, R."

Isocitrate dehydrogenase mutations in myeloid malignancies by Medeiros, B C, Fathi, A T, DiNardo, C D, Pollyea, D A, Chan, S M, Swords, R

“…Alterations to genes involved in cellular metabolism and epigenetic regulation are implicated in the pathogenesis of myeloid malignancies. Recurring mutations…”
Get full text

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia by Swords, R, Freeman, C, Giles, F

“…Acute myeloid leukemia (AML) is a highly heterogenous disease with multiple signaling pathways contributing to its pathogenesis. A key driver of AML is the…”
Get full text

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia by Giles, F J, O'Dwyer, M, Swords, R

“…Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that…”
Get full text

Targeting HSP90 for cancer therapy by Mahalingam, D, Swords, R, Carew, J S, Nawrocki, S T, Bhalla, K, Giles, F J

“…Heat-shock proteins (HSPs) are molecular chaperones that regulate protein folding to ensure correct conformation and translocation and to avoid protein…”
Get full text

Novel myelofibrosis treatment strategies: potential partners for combination therapies by Stein, B L, Swords, R, Hochhaus, A, Giles, F

“…Of the myeloproliferative neoplasms (MPNs), myelofibrosis (MF) is associated with the greatest symptom burden and poorest prognosis and is characterized by…”
Get full text

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia by Giles, F J, Swords, R T, Nagler, A, Hochhaus, A, Ottmann, O G, Rizzieri, D A, Talpaz, M, Clark, J, Watson, P, Xiao, A, Zhao, B, Bergstrom, D, Le Coutre, P D, Freedman, S J, Cortes, J E

“…MK-0457, an Aurora kinase and BCR–ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number…”
Get full text

Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary by Watts, J M, Wang, X V, Swords, R T, Paietta, E, Douer, D, Lugar, S M, Fernandez, H F, Rowe, J M, Lazarus, H M, Tallman, M S, Litzow, M R

Get full text

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes by Swords, R T, Watts, J, Erba, H P, Altman, J K, Maris, M, Anwer, F, Hua, Z, Stein, H, Faessel, H, Sedarati, F, Dezube, B J, Giles, F J, Medeiros, B C, DeAngelo, D J

Get full text

P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3‐MUTATED R/R AML (KB‐LANRA 1001) by Stein, E. M., Patel, A., Michaelis, L. C., Schiller, G., Swords, R., Carvajal, L. A., Bray, G., DiMartino, J., Levy, M. Y.

Get full text

Acute leukemia in adult Hispanic Americans: a large-population study by Swords, R, Sznol, J, Elias, R, Watts, J, Zelent, A, Martin, E, Vargas, F, Bethel-Ellison, S, Kobetz, E

Get full text

Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy by Swords, R, O'Rafferty, C, Giles, F, Browne, P

Get full text

Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP) by Swords, R., Power, D., Fay, M., O'Donnell, R., Murphy, P.T.

Get full text

Troxacitabine in acute leukemia by Swords, R, Giles, F

“…Troxacitabine (Troxatyl; BCH-4556; (-)-2'-deoxy-3'-oxacytadine) is the first synthetic l-nucleoside enantiomer to demonstrate broad spectrum cytotoxic…”
Get more information

The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No. 1

“…The Age-Related Eye Disease Study (AREDS) was initially conceived as a long-term multicenter, prospective study of the clinical course of age-related macular…”
Get full text

Myelodysplastic patients with raised percentage of hypochromic red cells have evidence of functional iron deficiency by Murphy, P T, Quinn, J P, O'Donghaile, D, Swords, R, O'Donnell, J R

“…Raised percentage hypochromic red cells (%HRC) were detected at diagnosis in 10 of 34 consecutive patients with low-risk myelodysplastic syndrome (MDS)…”
Get full text

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML by DiNardo, Courtney D, Stein, Eytan M, de Botton, Stéphane, Roboz, Gail J, Altman, Jessica K, Mims, Alice S, Swords, Ronan, Collins, Robert H, Mannis, Gabriel N, Pollyea, Daniel A, Donnellan, Will, Fathi, Amir T, Pigneux, Arnaud, Erba, Harry P, Prince, Gabrielle T, Stein, Anthony S, Uy, Geoffrey L, Foran, James M, Traer, Elie, Stuart, Robert K, Arellano, Martha L, Slack, James L, Sekeres, Mikkael A, Willekens, Christophe, Choe, Sung, Wang, Hongfang, Zhang, Vickie, Yen, Katharine E, Kapsalis, Stephanie M, Yang, Hua, Dai, David, Fan, Bin, Goldwasser, Meredith, Liu, Hua, Agresta, Sam, Wu, Bin, Attar, Eyal C, Tallman, Martin S, Stone, Richard M, Kantarjian, Hagop M

“…Among patients with IDH1 -mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from…”
Get full text

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9

“…Experimental and observational data suggest that micronutrients with antioxidant capabilities may retard the development of age-related cataract. To evaluate…”
Get more information

Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia by Swords, R, Fay, M, O'Donnell, R., Murphy, P. T.

Get full text

Treatment of refractory fludarabine induced autoimmune haemolytic with the anti‐cd20 monoclonal antibody rituximab by SWORDS, R., NOLAN, A., FAY, M., QUINN, J., O'DONNELL, R., MURPHY, P. T.

“…Summary A patient with cold‐type autoimmune haemolytic anaemia for 8 years developed progressive B cell chronic lymphocytic leukaemia (CLL). Despite the risk…”
Get full text

CML clonal evolution with resistance to single agent imatinib therapy by SWORDS, R., QUINN, J., FAY, M., O'DONNELL, R., GOLDMAN, J., MURPHY, P. T.

“…Summary We describe a 58‐year‐old male diagnosed with chronic myeloid leukaemia (CML) who failed to have a cytogenetic response to interferon‐α and…”
Get full text